Nasdaq · CIK 0001661998
QTTB Q32 Bio Inc.
Insider trading from SEC Form 4. Last filing Jun 16, 2026. Close $8.34 on Oct 9, 2026, +332% from the 52-week low and -61% from the high.
Q32 Bio Inc. (QTTB) has 38 SEC Form 4 filings on file from 13 insiders, the latest filed on Jun 16, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.
10 open-market trades have been scored at QTTB. The newest: Orbimed Advisors LLC (director and 10% owner) bought $15M of stock on May 28, 2026, filed Jun 1, 2026, scored 57 (moderate). 2 insiders bought within 14 days of each other around May 28, 2026.
QTTB closed at $8.34 on Oct 9, 2026, 332% above its 52-week low and 61% below its 52-week high.
2 Form 144 notices of planned sales are on file, the latest filed Dec 2, 2025.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at Q32 Bio Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 57Moderate | Orbimed Advisors LLC director, owner buy | $15M 1,875,000 shares | +83% | +658% from low-20% from high | |
| 62Notable | Diyong Xu director, owner buy | $15M 1,875,000 shares | +83% | +658% from low-20% from high | |
| 42Moderate | Lee Kalowski CFO and President sell | $18k 3,995 shares | -10% | +248% from low0% from high | |
| 46Moderate | Jodie Pope Morrison CEO sell | $45k 9,896 shares | -10% | +248% from low0% from high | |
| 30Weak | Shelia M. Violette Chief Scientific Officer sell | $13k 2,815 shares | -5% | +248% from low0% from high | |
| 40Moderate | Lee Kalowski CFO and President sell | $31k 9,072 shares | -19% | - | |
| 47Moderate | Jodie Pope Morrison CEO sell | $78k 22,506 shares | -19% | - | |
| 37Weak | Lee Kalowski CFO and President sell | $7,636 4,240 shares | -8% | - | |
| 40Moderate | Jodie Pope Morrison CEO sell | $19k 10,494 shares | -8% | - | |
| 30Weak | Shelia M. Violette Chief Scientific Officer sell | $5,385 2,990 shares | -5% | - |
Planned sales
Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales
| Filed | Seller | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Dec 2, 2025 | LEE KALOWSKI Officer | 9,072 0.07% of outstanding | $31k | Dec 2, 2025 | none |
| Dec 2, 2025 | JODIE MORRISON Officer, Director | 22,506 0.18% of outstanding | $78k | Dec 2, 2025 | none |
Transactions
The newest 50 of 70 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 12, 2026 | Sven Ante Lundberg director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Diyong Xu director, owner | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Mark T Iwicki director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Isaac Manke director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | David S. Grayzel director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Arthur Tzianabos director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| Jun 12, 2026 | Mary Thistle director | AGrant or award Stock Option (Right to Buy)derivative | +9,810 | $0.00 | $0 | 9,810 | Jun 16, 2026 |
| May 28, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,250,000 | $8.00 | $10M | 3,502,987 | Jun 1, 2026 |
| May 28, 2026 | Diyong Xu director, owner | POpen-market purchase Common Stockindirect: See footnotes | +1,250,000 | $8.00 | $10M | 3,502,987 | Jun 1, 2026 |
| May 28, 2026 | Diyong Xu director, owner | POpen-market purchase Common Stockindirect: See footnotes | +625,000 | $8.00 | $5.0M | 625,000 | Jun 1, 2026 |
| May 28, 2026 | Orbimed Advisors LLC director, owner | POpen-market purchase Common Stockindirect: See footnotes | +625,000 | $8.00 | $5.0M | 625,000 | Jun 1, 2026 |
| Feb 24, 2026 | Lee Kalowski CFO and President | AGrant or award Common Stock | +53,250 | $0.00 | $0 | 89,193 | Mar 20, 2026 |
| Feb 24, 2026 | Jodie Pope Morrison CEO | AGrant or award Common Stock | +132,000 | $0.00 | $0 | 221,104 | Mar 20, 2026 |
| Feb 24, 2026 | Shelia M. Violette Chief Scientific Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 93,069 | Mar 20, 2026 |
| Feb 25, 2026 | Lee Kalowski CFO and President | SOpen-market sale Common Stock | -3,995 | $4.51 | $18k | 35,943 | Feb 27, 2026 |
| Feb 25, 2026 | Jodie Pope Morrison CEO | SOpen-market sale Common Stock | -9,896 | $4.51 | $45k | 89,104 | Feb 27, 2026 |
| Feb 25, 2026 | Shelia M. Violette Chief Scientific Officer | SOpen-market sale Common Stock | -2,815 | $4.51 | $13k | 55,569 | Feb 27, 2026 |
| Jan 15, 2026 | David S. Grayzel director | AGrant or award Stock Option (Right to Buy)derivative | +16,363 | $2.75 | $45k | 16,363 | Jan 30, 2026 |
| Jan 15, 2026 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +23,272 | $2.75 | $64k | 23,272 | Jan 30, 2026 |
| Jan 15, 2026 | Sven Ante Lundberg director | AGrant or award Stock Option (Right to Buy)derivative | +20,363 | $2.75 | $56k | 20,363 | Jan 30, 2026 |
| Dec 2, 2025 | Jodie Pope Morrison CEO | SOpen-market sale Common Stock | -22,506 | $3.46 | $78k | 99,000 | Dec 4, 2025 |
| Dec 2, 2025 | Lee Kalowski CFO and President | SOpen-market sale Common Stock | -9,072 | $3.46 | $31k | 39,938 | Dec 4, 2025 |
| Oct 23, 2025 | Mark T Iwicki director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | David S. Grayzel director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Sven Ante Lundberg director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Isaac Manke director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Arthur Tzianabos director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Mary Thistle director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Oct 23, 2025 | Diyong Xu director | AGrant or award Stock Option (Right to Buy)derivative | +53,521 | $0.00 | $0 | 53,521 | Oct 27, 2025 |
| Aug 26, 2025 | Lee Kalowski CFO and President | SOpen-market sale Common Stock | -4,240 | $1.80 | $7,636 | 49,010 | Aug 28, 2025 |
| Aug 26, 2025 | Jodie Pope Morrison CEO | SOpen-market sale Common Stock | -10,494 | $1.80 | $19k | 121,506 | Aug 28, 2025 |
| Aug 26, 2025 | Shelia M. Violette Chief Scientific Officer | SOpen-market sale Common Stock | -2,990 | $1.80 | $5,385 | 58,384 | Aug 28, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -5,431 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 24, 2025 | Lee Kalowski CFO and President | AGrant or award Common Stock | +53,250 | $0.00 | $0 | 53,250 | Feb 27, 2025 |
| Feb 24, 2025 | Lee Kalowski CFO and President | DDisposition to issuer Stock Option (Right to Buy)derivative | -16,901 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +5,431 | $0.00 | $0 | 5,431 | Feb 27, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -1,947 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 24, 2025 | Lee Kalowski CFO and President | AGrant or award Stock Option (Right to Buy)derivative | +16,901 | $0.00 | $0 | 16,901 | Feb 27, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +1,947 | $0.00 | $0 | 1,947 | Feb 27, 2025 |
| Feb 24, 2025 | Lee Kalowski CFO and President | DDisposition to issuer Stock Option (Right to Buy)derivative | -161,323 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,767 | $0.00 | $0 | 0 | Feb 27, 2025 |
| Feb 24, 2025 | Lee Kalowski CFO and President | AGrant or award Stock Option (Right to Buy)derivative | +161,323 | $0.00 | $0 | 161,323 | Feb 27, 2025 |
| Feb 24, 2025 | Kathleen Laporte director | AGrant or award Stock Option (Right to Buy)derivative | +12,767 | $0.00 | $0 | 12,767 | Feb 27, 2025 |
| Feb 24, 2025 | Jason Campagna Chief Medical Officer | AGrant or award Common Stock | +37,500 | $0.00 | $0 | 37,500 | Feb 26, 2025 |
| Feb 24, 2025 | Mark T Iwicki director | DDisposition to issuer Stock Option (Right to Buy)derivative | -37,222 | $0.00 | $0 | 0 | Feb 26, 2025 |
| Feb 24, 2025 | David S. Grayzel director | DDisposition to issuer Stock Option (Right to Buy)derivative | -12,767 | $0.00 | $0 | 0 | Feb 26, 2025 |
| Feb 24, 2025 | Jason Campagna Chief Medical Officer | DDisposition to issuer Stock Option (Right to Buy)derivative | -87,738 | $0.00 | $0 | 0 | Feb 26, 2025 |
| Feb 24, 2025 | David S. Grayzel director | AGrant or award Stock Option (Right to Buy)derivative | +12,767 | $0.00 | $0 | 12,767 | Feb 26, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Jason CampagnaChief Medical Officer
- David S. Grayzeldirector
- Mark T Iwickiceo, officer, director
- Lee KalowskiCFO and President
- Kathleen Laportedirector
- Sven Ante Lundbergceo, president, officer, director
- Isaac Mankedirector
- Jodie Pope MorrisonCEO
- Orbimed Advisors LLCdirector, owner
- Arthur Tzianabosdirector, chair, officer
- Mary Thistledirector
- Shelia M. VioletteChief Scientific Officer
- Diyong Xudirector, owner
Questions about QTTB
Answered from the filings on this page, as of the latest one.
Are insiders buying QTTB?
No. In the last 90 days no insider at Q32 Bio Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.
Who was the last insider to trade QTTB on the open market?
Orbimed Advisors LLC (director and 10% owner) bought $15M of QTTB on May 28, 2026 and filed the Form 4 on Jun 1, 2026. InsiderTell scored 57 (moderate), with 2 insiders on the same side within 14 days.
How many insiders file Form 4 at Q32 Bio Inc.?
13 people have filed a Form 4 at Q32 Bio Inc., among them Jason Campagna (Chief Medical Officer), David S. Grayzel (director), Mark T Iwicki (CEO and director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.